Ocata Therapeutics Approved For Listing On NASDAQ
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has received notice that the NASDAQ Listing Qualifications Department has approved its application to list the Company’s common stock on the NASDAQ Global Market, effective with the opening of trading today, February 26, 2015, under the ticker symbol “OCAT”.
“This is a significant step in the Company’s evolution and crucial to our long-term corporate strategy,” stated Ted Myles, Chief Operating Officer and Chief Financial Officer, of Ocata. “The NASDAQ Global Market is the right place for a biotechnology company like Ocata, with an advanced clinical stage pipeline, to be listed and we are pleased to become part of this prestigious exchange.”
Help employers find you! Check out all the jobs and post your resume.
“This is a significant step in the Company’s evolution and crucial to our long-term corporate strategy,” stated Ted Myles, Chief Operating Officer and Chief Financial Officer, of Ocata. “The NASDAQ Global Market is the right place for a biotechnology company like Ocata, with an advanced clinical stage pipeline, to be listed and we are pleased to become part of this prestigious exchange.”
Help employers find you! Check out all the jobs and post your resume.